JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. Stock

Equities

JSP

THA520010002

Pharmaceuticals

End-of-day quote Thailand S.E. 18:00:00 2024-05-02 EDT 5-day change 1st Jan Change
2.8 THB +1.45% Intraday chart for JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. +19.66% +21.74%

Financials

Sales 2022 436M 11.89M 16.26M Sales 2023 594M 16.19M 22.14M Capitalization 1.09B 29.72M 40.66M
Net income 2022 -17M -463K -633K Net income 2023 -1M -27.23K -37.25K EV / Sales 2022 3.44 x
Net cash position 2022 146M 3.96M 5.42M Net Debt 2023 270M 7.35M 10.05M EV / Sales 2023 2.29 x
P/E ratio 2022
-90.5 x
P/E ratio 2023
-851 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 28.73%
More Fundamentals * Assessed data
Dynamic Chart
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Establishes a New Subsidiary and Investing in A Subsidiary CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. completed the acquisition of 52.8% stake in Grace Water Med Co., Ltd from NCL International Logistics Public Company Limited. CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. agreed to acquire 52.8% stake in Grace Water Med Co., Ltd from NCL International Logistics Public Company Limited for THB 43.9 million. CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Proposes to Omit the Annual Dividend Payment for the Year 2022 CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Jsp Pharmaceutical Manufacturing Public Co., Ltd. Approves the Establishment of the Company's Subsidiary CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. agreed to acquire 65% stake in CDIP Public Company Limited from group of sellers for THB 250 million. CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
187,687,500 Ordinary Shares of JSP Pharmaceutical Manufacturing Public Company Limited are subject to a Lock-Up Agreement Ending on 2-NOV-2022. CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
JSP Pharmaceutical Manufacturing Public Co., Ltd. Announces Establishment of New Subsidiary CI
More news
1 day+1.45%
1 week+19.66%
1 month+13.82%
3 months+21.74%
6 months+37.25%
Current year+21.74%
More quotes
1 week
2.46
Extreme 2.46
2.98
1 month
2.20
Extreme 2.2
2.98
Current year
2.08
Extreme 2.08
2.98
1 year
1.90
Extreme 1.9
3.64
3 years
1.90
Extreme 1.9
12.10
5 years
1.90
Extreme 1.9
12.10
10 years
1.90
Extreme 1.9
12.10
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18-12-02
Director of Finance/CFO - 18-12-02
Chief Operating Officer - 19-02-05
Members of the board TitleAgeSince
Director/Board Member 70 21-03-23
Chairman - 20-07-20
Director/Board Member - 18-12-02
More insiders
Date Price Change Volume
24-05-02 2.8 +1.45% 1 127 319
24-05-02 2.76 -1.43% 2,109,332
24-04-30 2.8 +12.90% 6,998,380
24-04-29 2.48 -1.59% 621,926
24-04-26 2.52 +7.69% 1,387,622

End-of-day quote Thailand S.E., May 02, 2024

More quotes
JSP Pharmaceutical Manufacturing (Thailand) PCL is a Thailand-based company, which manufactures and distributes conventional medicines. The Company manufactures and distributes products under customer’s brand name (OEM), as well as under the Company’s brand name. The Company develops, manufactures and sells conventional and traditional medicines, herbal products and dietary supplements, providing a range of services covering the manufacturer and the seller of the products under both customers’ trademark (OEM) and the seller of the products under the Company’s trademark (Own Brand). The Company develops herbal products, dietary supplements with natural extracts and plant-based protein under brand name Supap Osot, and dietary supplements such as using new raw materials or having new production process for both beauty and health under brand name EVITON. The Company’s subsidiary, Caresutic Co., Ltd., is engaged in manufacturing and distribution of dietary supplements and cosmetic products.
More about the company